Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




PET Scans Reveal Estrogen-Producing Hotspots in Human Brain

By LabMedica International staff writers
Posted on 29 Nov 2010
Researchers at a U.S. More...
National lab have demonstrated that a molecule "tagged” with a radioactive form of carbon can be used to image aromatase, an enzyme responsible for the production of estrogen, in the human brain. Moreover, the research revealed that the areas of the brain where aromatase is concentrated might be unique to humans.

"The original purpose of the study was to expand our use of this radiotracer, N-methyl-11C vorozole,” said Dr. Anat Biegon, a neurobiologist at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory (Upton, NY, USA). "Proving that a radiotracer like vorozole can be used for brain-imaging studies in humans would be a gateway to new research on estrogen in the brain. You cannot look at these brain pathways in living humans in any other way.”

Vorozole binds to aromatase, a vital catalyst in the biosynthesis of estrogen. Since estrogen is implicated in a range of conditions and pathologies, from breast cancer to Alzheimer's disease, studying its production in the human body using noninvasive imaging techniques such as positron emission tomography (PET) imaging can be a useful diagnostic and investigative tool. This is the first study to demonstrate that vorozole is a useful radiotracer for studying estrogen-producing hotspots in the human brain.

The investigators employed PET imaging to scan the brains of six young, healthy nonsmoking subjects--three men and three women. Researchers scanned the female subjects at either the midcycle or the early follicular phase of the menstrual cycle, to incorporate variation in plasma estrogen levels. Before scanning, all subjects received an injection containing a radiolabeled form of vorozole, synthesized and purified by radiochemists at Brookhaven. The men underwent a second scan after being administered an aromatase inhibitor. As expected, subjects who received the inhibitor demonstrated low concentrations of radioactive vorozole, indicating lower availability of aromatase, compared to those not exposed to the inhibitor.

The scientists found a shocker, however, in the "geographic” (anatomic) distribution of aromatase in the brain. The highest levels of aromatase appeared in the thalamus and then the medulla, in a pattern that was consistent across all six subjects. This differs from what researchers have observed previously in animal studies, where aromatase is concentrated in smaller regions, principally the amygdala and preoptic areas. "This started as a simple tool development study and now it's turned out to be much more interesting than that,” Dr. Biegon noted. "The question that's raised is what is aromatase doing in these particular brain regions?”

To answer this, Dr. Biegon and her colleagues have already started evaluating a larger group of 30 subjects. They will examine differences in brain aromatase related to a range of factors including age, sex, personality, and memory. Beginning with healthy subjects and advancing to patients with specific conditions and diseases, they plan to examine the role of estrogen in the brain in relation to disorders and diseases such as unusual aggression, breast cancer, and Alzheimer's disease.

The research was published in the November 2010 issue of the journal Synapse.

Related Links:

Brookhaven National Laboratory


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automatic CLIA Analyzer
Shine i6000
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.